The twin designations are designed to speed up the development and review of promising medicines targeting serious conditions with high unmet need
Steady growth led by biologics and CRDMO business, EBITDA margin at 25% with continued investments in ADCs, peptides, and digital capabilities
Patients receiving ELREXFIO largely remained free from disease progression during the interim analysis
The agreement could rise to $900 million if key commercial milestones are met
CPHI India from 23–25 November 2026 at Yashobhoomi (India International Convention and Expo Centre), while PMEC India from 24–26 November 2026 at India Expo Mart
Company confirms seized products were not from its authorised supply chain and urges patients to purchase medicines only through licensed pharmacies
SPARC enters definitive agreement to monetise rare paediatric disease PRV, unlocking capital for R&D and strategic growth
New medical and wellness centre combines on-site care with telehealth to support industrial workforce and surrounding communities
Landmark agreement opens market access, mobility pathways, and institutional collaboration for Ayurveda, Yoga, and holistic healthcare services
In Q4 FY26, the company reported revenue from operations of Rs 176.9 crore, marking a 23.6% year-on-year growth
Subscribe To Our Newsletter & Stay Updated
